Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 3Phase 3 1Phase 1 1

Status

Recruiting 3Active not recruiting 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Gynecologic 1Dermatologic 1

Conditions

Ovarian Neoplasms 1Neoplasms 1Melanoma 1Glioblastoma 1Brain Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × defactinib × Clear all
NCT06630260 2026-01-21

5G-RUBY

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
182 enrolled
CNS

Glioblastoma

NCT06194929 2025-12-03

DETERMINE

University of Utah

Phase 1/2 Recruiting
33 enrolled
CNSDermatologic

Brain Neoplasms, Melanoma

NCT03287271 2024-08-12

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California, San Diego

Phase 1/2 Recruiting
90 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡